GlassScriptPhysician profile
Kristen Maxwell
NPI 1396353355
$3,554.96
in general payments reported to CMS, 2019-2025
34 companies · $654 in 2025
The $654 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $575 · 2022: $684 · 2023: $908 · 2024: $735 · 2025: $654.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,296.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,296.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $781.36 | 2021-2025 | |
| Glaxosmithkline, LLC. | $400.37 | 2021-2025 | Trelegy Ellipta, Bexsero, Arexvy |
| Gilead Sciences, INC. | $255.63 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $211.21 | 2021-2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $186.60 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $184.69 | 2021-2024 | Jardiance, Ofev |
| Daiichi Sankyo INC. | $175.46 | 2021-2023 | Injectafer |
| Corcept Therapeutics | $167.55 | 2023-2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $151.67 | 2024-2025 | Gvoke Hypopen |
| Exact Sciences Corporation | $151.48 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $124.91 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $90.45 | 2021-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $83.60 | 2025 | Fanapt |
| Alkermes, INC. | $78.80 | 2022-2023 | Vivitrol |
| Teva Pharmaceuticals USA, INC. | $45.82 | 2022-2023 | Ajovy, Austedo Xr |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $42.99 | 2024-2025 | Caplyta |
| Novo Nordisk INC | $41.32 | 2024-2025 | Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $39.18 | 2023 | |
| Indivior INC. | $35.18 | 2024-2025 | Sublocade |
| Pfizer INC. | $35.11 | 2023-2025 | |
| Vertex Pharmaceuticals Incorporated | $35.00 | 2025 | |
| Astellas Pharma US INC | $32.51 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.90 | 2025 | Xifaxan |
| Medtronic, INC. | $19.90 | 2024 | Minimed 780g |
| Mylan Specialty L.P. | $19.57 | 2024 | Yupelri |
| Abbott Laboratories | $19.53 | 2025 | Freestyle Libre 3 |
| Verona Pharma, INC. | $18.15 | 2025 | Ohtuvayre |
| Sanofi Pasteur INC. | $16.16 | 2021 | |
| Genentech USA, INC. | $15.83 | 2021 | |
| Hikma Pharmaceuticals USA | $15.80 | 2022 | |
| Dexcom, INC. | $14.60 | 2025 | Dexcom G6 Transmitter |
| Amneal Pharmaceuticals LLC | $13.84 | 2024 | Unithroid |
| Amgen INC. | $13.57 | 2024 | Otezla, Repatha |
| Scilex Pharmaceuticals INC. | $13.22 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristen Maxwell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.